Mrs Doris Putman Maise, RPH | |
1152 Eastlake Blvd, Tarrant City, AL 35217 | |
(205) 841-6421 | |
(205) 841-2405 |
Full Name | Mrs Doris Putman Maise |
---|---|
Gender | Female |
Speciality | Pharmacist |
Location | 1152 Eastlake Blvd, Tarrant City, Alabama |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1972728624 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
183500000X | Pharmacist | 7115 (Alabama) | Primary |
Mailing Address | Practice Location Address |
---|---|
Mrs Doris Putman Maise, RPH 821 Crosshill Lane, Warrior, AL 35180-5540 Ph: (205) 647-6635 | Mrs Doris Putman Maise, RPH 1152 Eastlake Blvd, Tarrant City, AL 35217 Ph: (205) 841-6421 |
News Archive
A potential drug to treat heart attacks and to prevent heart failure - for which no cure currently exists - may result from pioneering research by a University of Guelph professor.
MED3OOO, a leading healthcare management and technology company, and Acryness, a document processing and mailing organization, announce a strategic partnership to provide patient-friendly and intelligent content-driven statement solutions. The partnership will provide the MED3OOO QuikBill patient billing solutions, powered by Acryness, to MED3OOO's Revenue Cycle Management and ASP Practice Management clients.
Long term care insurance may not seem like headline news or talk-show fare, but Denise Gott pursues the topic with passion and flair. "I'm on a mission to wake up America," she says. Her message is now appearing on CNN newscasts in the nation's airports and broadcasts on Delta Air Line flights. Gott is Chairman of the Board of LTC Financial Partners LLC (LTCFP) - http://www.ltcfp.com - one of the nation's largest and most experienced long-term care insurance agencies.
BioMarin Pharmaceutical Inc. announced today that it has acquired ZyStor Therapeutics, Inc. (ZyStor), a privately-held biotechnology company developing enzyme replacement therapies (ERT) for the treatment of lysosomal storage disorders. ZyStor's lead product candidate is ZC-701, a novel fusion of insulin-like growth factor 2 and alpha glucosidase (IGF2-GAA) in development for Pompe disease.
Medical students from the University of Leicester's Medical School have developed a free educational resource for medical students and junior doctors that teaches valuable surgical skills they will need during their training.
› Verified 2 days ago